Vergoeding 2020-2024 voor ATC-subgroep H01CB : Somatostatine en analogen
- Raming voor de totale Zvw-populatie
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| H01CB02 Octreotide (Sandostatine ®) | 21.130.800 | 15.103.300 | 14.497.400 | 14.442.400 | 13.942.000 |
| H01CB03 Lanreotide (Somatuline ®) | 25.080.900 | 22.420.300 | 21.805.900 | 18.729.400 | 17.489.500 |
| H01CB05 Pasireotide (Signifor ®) | 2.433.800 | 2.262.300 | 2.366.300 | 2.388.700 | 2.394.700 |
| Totaal | 48.645.500 | 39.785.900 | 38.669.600 | 35.560.500 | 33.826.200 |